Abstract
A Bayesian framework for group testing under dilution effects is introduced. This work has particular relevance given the pressing public health need to enhance testing capacity for COVID-19, and the need for wide-scale and repeated testing for surveillance. The proposed Bayesian approach allows for dilution effects in group testing and for general test response distributions beyond just binary outcomes. It is shown that even with strong dilution effects, an intuitive and simple-to-implement group testing selection rule, referred to as the Bayesian halving algorithm, has attractive optimal properties. A web-based calculator is introduced to assist and guide decisions on when and how to pool under various conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants NSF DRL1561716, R01 MH65538 and UL1TR002548
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work does not involve data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.